Stockscreener 앱 받기
0.824
4.84%
-0.0419
전일 마감가:
$0.8659
열려 있는:
$0.86
하루 거래량:
117.91K
Relative Volume:
0.72
시가총액:
$103.95M
수익:
-
순이익/손실:
$-70.78M
주가수익비율:
-1.4714
EPS:
-0.56
순현금흐름:
$-61.27M
1주 성능:
+17.71%
1개월 성능:
+13.92%
6개월 성능:
-64.17%
1년 성능:
-71.78%
1일 변동 폭
$0.8078
$0.8821
1주일 범위
$0.7001
$1.01
52주 변동 폭
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
명칭
Nautilus Biotechnology Inc
전화
206-333-2001
주소
2701 EASTLAKE AVE EAST, SEATTLE
NAUT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.824 | 88.30M | 0 | -70.78M | -61.27M | -0.56 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-06-27 | 개시 | Guggenheim | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2022-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 개시 | Cowen | Outperform |
| 2021-08-04 | 개시 | Goldman | Neutral |
| 2021-07-13 | 개시 | Jefferies | Buy |
모두보기
Nautilus Biotechnology Inc 주식(NAUT)의 최신 뉴스
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Nautilus Biotechnology And 2 Other Penny Stocks With Promising Potential - Yahoo Finance
Insiders continue to buy Nautilus Biotechnology, Inc. (NASDAQ:NAUT) and now own 31% shares - simplywall.st
Nautilus Biotechnology chief scientist buys $9,885 in common stock By Investing.com - Investing.com Nigeria
Hsbc Holdings PLC Has $92,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Barclays PLC Buys 19,030 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology chief scientist buys $9,885 in common stock - Investing.com
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Barchart.com
Renaissance Technologies LLC Acquires 95,521 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
JPMorgan Chase & Co. Raises Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Reports Q1 2025 Financial Results - TipRanks
Nautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancements - MSN
Nautilus Biotech’s Earnings Call Highlights Progress and Promise - TipRanks
Nautilus Biotechnology Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beat - Investing.com
Nautilus Biotechnology (NAUT) Anticipates Tau Proteoform Assay L - GuruFocus
Nautilus Biotechnology Posts Qtrly Loss Per Share $0.13 - marketscreener.com
Nautilus Biotechnology (NAUT) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday - Defense World
Nautilus Biotechnology Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Increases By 20.5% - Defense World
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 - The Manila Times
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - MarketScreener
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence By Investing.com - Investing.com South Africa
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence - Investing.com India
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating By Investing.com - Investing.com South Africa
Nautilus Biotechnology Reports 2024 Financial Results - TipRanks
Seattle's Nautilus Biotechnology lays off 16% of its staff - The Business Journals
Nautilus Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Nautilus Q4 2024 highlights platform delay - Investing.com
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Nautilus Cuts 16% of Workforce as Biotech Platform Launch Slips to 2026What's Next? - StockTitan
Nautilus Biotechnology Announces Board Changes for 2025 - TipRanks
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Exclusive: Nautilus Biotech Unveils Next-Gen Protein Analysis Breakthrough at Major Healthcare Summit - StockTitan
Nautilus Biotechnology Inc (NAUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nautilus Biotechnology Inc 주식 (NAUT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
1.54%
7.58%
자본화:
|
볼륨(24시간):